Guideline · Consensus statement
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy.
- Cardiovascular
- Haematology and oncology
- Infection and sepsis
- Medical
- Neurology
- Nursing
- Oncology emergencies
- Sepsis
- Shock
This guideline is from 2019, more than five years ago. Check whether a newer version exists and which version your unit follows.
Summary
Consensus guidelines from the PALISI HSCT Subgroup and the MD Anderson CARTOX Program on the care of children and young adults receiving CAR T cell therapy for relapsed or refractory CD19+ acute lymphoblastic leukaemia. It addresses the unique and often severe toxicities of this therapy, which can cause rapid cardiorespiratory and neurological deterioration. The document emphasises multidisciplinary vigilance and the health-care infrastructure needed as these therapies move from research into standard care. Relevant to PICU teams who receive these patients when they deteriorate.
Summary written for PICUlearn. Always read the original.
- Licence:
- Open (Creative Commons)
The full text of this openly licensed guideline is available to PICUlearn members, and Peeky can answer questions from it.
Guidelines are shown for education. Follow your unit's own guidance and senior advice.